Coherus Biosciences | CHRS - Sales Revenues

Stock Price
1.61
Daily Change
-0.40 -19.90%
Monthly
0.63%
Yearly
36.44%
Q1 Forecast
2.39

Coherus Biosciences reported $7.6M in Sales Revenues for its fiscal quarter ending in March of 2025.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Acadia Pharmaceuticals USD 278.6M 14M Sep/2025
Akebia Therapeutics USD 57.34M 10.84M Mar/2025
ALKERMES USD 394.2M 3.5M Sep/2025
Alnylam Pharmaceuticals USD 1.1B 150M Dec/2025
Amarin USD 49.67M 23.07M Sep/2025
Amgen USD 9.9B 340M Dec/2025
Baxter International USD 2.97B 130M Dec/2025
Biogen USD 2.28B 250M Dec/2025
BioMarin Pharmaceutical USD 776M 49M Sep/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Coherus Biosciences USD 7.6M 46.54M Mar/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Fujifilm JPY 857.35B 34.47B Dec/2025
Gilead Sciences USD 7.93B 130M Dec/2025
Ironwood Pharmaceuticals USD 122.06M 36.82M Sep/2025
Merck USD 16.4B 880M Dec/2025
Myriad Genetics USD 205.7M 7.4M Sep/2025
Pacira USD 179.52M 1.58M Sep/2025
Perrigo USD 1.04B 16.3M Sep/2025
Pfizer USD 17.58B 880M Dec/2025
PTC Therapeutics USD 211M 32.1M Sep/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Sarepta Therapeutics USD 399.4M 211.69M Sep/2025
Teva Pharmaceutical Industries USD 14.63B 10M Dec/2025
Vertex Pharmaceuticals USD 3.19B 110M Dec/2025
Xencor USD 21M 22.61M Sep/2025
Zoetis USD 2.4B 0 Dec/2025